Dempze Nancy E Has $289,000 Stock Holdings in Relx Plc $RELX

Dempze Nancy E increased its position in shares of Relx Plc (NYSE:RELX) by 7.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,315 shares of the technology company’s stock after acquiring an additional 370 shares during the quarter. Dempze Nancy E’s holdings in Relx were worth $289,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Goldman Sachs Group Inc. lifted its stake in shares of Relx by 4.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,072,342 shares of the technology company’s stock valued at $205,287,000 after acquiring an additional 173,976 shares during the period. Ameriprise Financial Inc. increased its holdings in Relx by 8.3% in the first quarter. Ameriprise Financial Inc. now owns 3,041,132 shares of the technology company’s stock valued at $154,129,000 after purchasing an additional 234,094 shares during the last quarter. Northern Trust Corp increased its holdings in Relx by 9.2% in the first quarter. Northern Trust Corp now owns 2,394,097 shares of the technology company’s stock valued at $120,686,000 after purchasing an additional 202,509 shares during the last quarter. Natixis Advisors LLC increased its holdings in Relx by 0.5% in the first quarter. Natixis Advisors LLC now owns 1,208,467 shares of the technology company’s stock valued at $60,919,000 after purchasing an additional 5,875 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in Relx by 103.4% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 444,360 shares of the technology company’s stock valued at $22,400,000 after purchasing an additional 225,947 shares during the last quarter. Institutional investors and hedge funds own 15.02% of the company’s stock.

Relx Stock Up 0.9%

Shares of Relx stock opened at $45.84 on Thursday. Relx Plc has a 1 year low of $44.19 and a 1 year high of $56.33. The business has a 50-day moving average of $47.49 and a two-hundred day moving average of $50.87. The company has a market capitalization of $84.01 billion, a P/E ratio of 24.65, a price-to-earnings-growth ratio of 2.96 and a beta of 0.87. The company has a debt-to-equity ratio of 2.55, a current ratio of 0.47 and a quick ratio of 0.42.

Relx Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, September 16th. Investors of record on Friday, August 8th were issued a dividend of $0.2634 per share. The ex-dividend date was Friday, August 8th. This represents a dividend yield of 170.0%. Relx’s dividend payout ratio (DPR) is presently 28.49%.

Wall Street Analyst Weigh In

RELX has been the subject of a number of recent analyst reports. Morgan Stanley reiterated an “overweight” rating on shares of Relx in a report on Thursday, September 11th. Kepler Capital Markets upgraded Relx from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 18th. Wall Street Zen downgraded Relx from a “buy” rating to a “hold” rating in a report on Friday, September 5th. Barclays reiterated an “overweight” rating on shares of Relx in a report on Tuesday. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Relx in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company. According to data from MarketBeat.com, Relx presently has an average rating of “Buy”.

Relx Profile

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.